FFO
CRNX icon

Fortitude Family Office’s Crinetics Pharmaceuticals CRNX Stock Holding History

Fortitude Family Office’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$599 Buy
+16
New +$595 ﹤0.01% 1933
2025
Q2 		– Sell
-44
Closed -$1.48K – 2049
2025
Q1 		$1.48K Hold
44
– – ﹤0.01% 970
2024
Q4 		$2.25K Hold
44
– – ﹤0.01% 1010
2024
Q3 		$2.25K Hold
44
– – ﹤0.01% 981
2024
Q2 		$1.97K Hold
44
– – ﹤0.01% 807
2024
Q1 		$2.06K Hold
44
– – ﹤0.01% 816
2023
Q4 		$1.57K Buy
+44
New +$1.35K ﹤0.01% 902

Other funds holding CRNX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Fortitude Family Office's CRNX Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 16 shares worth $599. The stake represents ﹤0.01% of the portfolio and ranks #1933 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in CRNX as recently as Q1 2025.

Fortitude Family Office first reported a position in CRNX in Q4 2023 and has held it in 7 quarters since. The position peaked at $2.25K in Q4 2024. 32 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Fortitude Family Office held 16 shares of Crinetics Pharmaceuticals worth $599 as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Fortitude Family Office position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1933 holding.
  • Fortitude Family Office first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • Fortitude Family Office's Crinetics Pharmaceuticals position peaked at $2.25K in Q4 2024.
  • 32 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.